Rheumatoid arthritis: new insights into the role of synovial inflammation in joint destruction

References

• Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000;43:2619–33.
   PubMed Web of Science ®Google Scholar
• van Zeben D, Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC. Factors predicting outcome of rheumatoid arthritis: results of a followup study. J Ftheumatol 1993;20:1288–96.
   Google Scholar
• Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum 1996;39:1781–90.
   PubMed Web of Science ®Google Scholar
• Tak PP, Zvaifler NJ, Green DR, Firestein GS. Rheumatoid arthri-tis and p53: how oxidative stress might alter the course of inflammatory diseases. Immunol Today 2000;21:78–82.
   PubMedGoogle Scholar
• Burmester GR, Stuhlmuller B, Keyszer G, Kinne RW. Mono-nuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? Arthritis Rheum 1997;40:5–18.
   PubMed Web of Science ®Google Scholar
• Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001;107:7–11.
   PubMed Web of Science ®Google Scholar
• Van den Berg WB. Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin Arthritis Rheum 2001;30:7–16.
   PubMed Web of Science ®Google Scholar
• Tetlow LC, Woolley DE. Mast cells, cytokines, and metal-loproteinases at the rheumatoid lesion: dual immunolocalisation studies. Ann Rheum Dis 1995;54:896–903.
   PubMed Web of Science ®Google Scholar
• McCachren SS, Haynes BF, Niedel JE. Localization of collagenase mFtNA in rheumatoid arthritis synovium by in situ hybridization histochemistry. J Clin Immunol 1990;10:19–27.
   Google Scholar
• McCachren SS. Expression of metalloproteinases and metal-loproteinase inhibitor in human arthritic synovium. Arthritis Rheum 1991;34:1085–93.
   PubMed Web of Science ®Google Scholar
• Gravallese EM, Darling JM, Ladd AL, Katz JN, Glimcher LH. In situ hybridization studies of stromelysin and collagenase messen-ger RNA expression in rheumatoid synovium. Arthritis Rheum 1991;34:1076–84.
   Google Scholar
• Vincenti MP, Clark IM, Brinckerhoff CE. Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? Arthri-tis Rheum 1994;37:1115–26.
   PubMed Web of Science ®Google Scholar
• Konttinen YT, Ainola M, Valleala H, Ma J, Ida H, Mandelin J, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999;58:691–7.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Makino K, Takizawa M, Nakamura H, Fujimoto N, Moriya H, et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in rheumatoid synovium. Lab Invest 2000;80:677–87.
   PubMed Web of Science ®Google Scholar
• Pap T, Shigeyama Y, Kuchen S, Fernihough JK, Simmen B, Gay RE, et al. Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis. Arthritis Rheum 2000;43:1226–32.
   PubMed Web of Science ®Google Scholar
• Martel-Pelletier J, McCollum R, Fujimoto N, Obata K, Cloutier JM, Pelletier JP. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in os-teoarthritis and rheumatoid arthritis. Lab Invest 1994;70:807–15.
   Google Scholar
• Firestein GS. Mechanisms of tissue destruction and cellular activa-tion in rheumatoid arthritis. Curr Opin Ftheumatol 1992;4:348–54.
   PubMedGoogle Scholar
• Manicourt DH, Fujimoto N, Obata K, Thonar EJ. Levels of circu-lating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Rela-tionship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation. Arthritis Rheum 1995;38:1031–9.
   Google Scholar
• Smeets TJ, Kraan MC, Galjaard S, Youssef PP, Smith MD, Tak PP. Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA. Ann Rheum Dis 2001;60:561–5.
   PubMed Web of Science ®Google Scholar
• Katrib A, Tak PP, Bertouch JV, Cuello C, McNeil HP, Smeets TJ, et al. Expression of chemokines and matrix metalloproteinases in early rheumatoid arthritis. Ftheumatology (Oxford) 2001;40:988–94.
   PubMed Web of Science ®Google Scholar
• Cunnane G, FitzGerald 0, Hummel KM, Youssef PP, Gay RE, Gay S, et al. Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. Arthritis Rheum 2001;44: 1744–53.
   PubMed Web of Science ®Google Scholar
• Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995;333:142–6.
   Google Scholar
• Firestein GS, Paine MM, Littman BH. Gene expression (collage-nase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium. Quantitative analysis and effect of intraarticular corticosteroids. Arthritis Rheum 1991;34:1094–105.
   Google Scholar
• Wong P, Cuello C, Bertouch JV, Roberts-Thomson PJ, Ahern MJ, Smith MD, et al. The effects of pulse methylprednisolone on matrix metalloproteinase and tissue inhibitor of metalloproteinase-1 expression in rheumatoid arthritis. Ftheuma-tology (Oxford) 2000;39: 1067–73.
   Google Scholar
• Kraan MC, Reece FtJ, Barg EC, Smeets TJ, Farnell J, Rosenburg R, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospec-tive, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000;43:1820–30.
   Google Scholar
• Smeets TJM, Dayer JM, Kraan MC, Versendaal H, Chicheportiche R, Breedveld FC, et al. The effects of interferon-beta treatment on synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. Arthritis Rheum 2000;43: 270–4.
   PubMed Web of Science ®Google Scholar
• Smith MD, Kraan MC, Slavotinek J, Au V, Weedon H, Parker A, et al. Treatment-induced remission in rheumatoid arthritis patients is characterized by a reduction in macrophage content of synovial biopsies. Ftheumatology (Oxford) 2001;40:367–74.
   PubMed Web of Science ®Google Scholar
• Katrib A, Smith MD, Ahern MJ, Slavotinek J, Roberts-Thomson PJ, Cuello C, et al. Chemokine and matrix metalloproteinase ex-pression in rheumatoid arthritis patients achieving remission. Ftheumatology. In press. 2002.
   Google Scholar
• Mengshol JA, Mix KS, Brinckerhoff CE. Matrix metal-loproteinases as therapeutic targets in arthritic diseases. Bull's-eye or missing the mark? Arthritis Rheum 2002;46:13–20.
   Google Scholar
• Yamanishi Y, Firestein GS. Pathogenesis of rheumatoid arthritis: the role of synoviocytes. Rheum Dis Clin North Am 2001;27:355–71.
   PubMed Web of Science ®Google Scholar
• Lark MW, Bayne EK, Flanagan J, Harper CF, Hoerrner LA, Hutchinson NI, et al. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activ-ity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest 1997;100:93–106.
   Google Scholar
• Vankemmelbeke MN, Holen I, Wilson AG, Ilic MZ, Handley CJ, Kelner GS, et al. Expression and activity of ADAMTS-5 in synovium. Eur J Biochem 2001;268:1259–68.
   PubMedGoogle Scholar
• Abbaszade I, Liu RQ, Yang F, Rosenfeld SA, Ross OH, Link JR, et al. Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem 1999;274:23443–50.
   PubMed Web of Science ®Google Scholar
• Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 1999;284:1664–6.
   PubMed Web of Science ®Google Scholar
• Yamanishi Y, Boyle DL, Clark M, Maki RA, Tortorella MD, Amer EC, et al. Expression and regulation of aggrecanase in ar-thritis: the role of TGF-beta. J Immunol 2002;168:1405–12.
   PubMed Web of Science ®Google Scholar
• Little CB, Hughes CE, Curtis CL, Jones SA, Caterson B, Flannery CR, et al. Cyclosprin A inhibition of aggrecanase-mediated proteoglycan catabolism in articular cartilage. Arthritis Rheum 2002;46:124–9.
   PubMedGoogle Scholar
• Tak PP, Kummer JA, Hack CE, Daha MR, Smeets TJM, Erkelens GW, et al. Granzyme positive cytotoxic cells are specifically in-creased in early rheumatoid synovial tissue. Arthritis Rheum 1994;37:1735–43.
   PubMed Web of Science ®Google Scholar
• Muller-Ladner U, Kriegsmann J, Tschopp J, Gay RE, Gay S. Dem-onstration of granzyme A and perforin messenger RNA in the synovium of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:477–84.
   Google Scholar
• Smeets TJM, Dolhain RJEM, Breedveld FC, Tak PP. Analysis of the cellular infiltrates and expression of cytokines in synovial tissue from patients with rheumatoid arthritis and reactive arthritis. J Pathol 1998;186:75–81.
   PubMed Web of Science ®Google Scholar
• Tak PP, Spaeny-Dekking L, Kraan MC, Breedveld FC, Froelich CJ, Hack CE. The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA). Clin Exp Immunol 1999;116:366–70.
   PubMed Web of Science ®Google Scholar
• Froelich CJ, Zhang X, Turbov J, Hudig D, Winkler U, Hanna WL. Human granzyme B degrades aggrecan proteoglycan in matrix synthesized by chondrocytes. J Immunol 1993;151:7161–71.
   PubMed Web of Science ®Google Scholar
• Ronday HK, van der Laan WH, Tak PP, De Roos JA, Bank RA, TeKoppele JM, et al. Human granzyme B mediates cartilage proteoglycan degradation and is expressed at the invasive front of the synovium in rheumatoid arthritis. Ftheumatology (Oxford) 2001;40:55–61.
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Suson S, Hoxworth J, Hack EC, Peters KM, El-Gabalawi HS, et al. Elevated serum granzyme B levels are associated with erosions in patients with early rheumatoid arthritis. Arthritis Rheum 2000;43:5155.
   Google Scholar
• Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250–8.
   PubMed Web of Science ®Google Scholar
• Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Ar-thritis Rheum 2000;43:259–69.
   PubMed Web of Science ®Google Scholar
• Romas E, Bakharevski 0, Hards DK, Kartsogiannis V, Quinn JM, Ryan PF, et al. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 2000;43:821–6.
   Google Scholar
• Itonaga I, Fujikawa Y, Sabokbar A, Murray DW, Athanasou NA. Rheumatoid arthritis synovial macrophage-osteoclast differentia-tion is osteoprotegerin ligand-dependent. J Pathol 2000;192:97–104.
   Google Scholar
• Gravallese EM, Galson DL, Goldring SR, Auron PE. The role of TNF-receptor family members and other TFtAF-dependent recep-tors in bone resorption. Arthritis Res 2001;3:6–12.
   PubMedGoogle Scholar
• Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000;43:2523–30.
   PubMed Web of Science ®Google Scholar
• Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001;44:1003–12.
   PubMed Web of Science ®Google Scholar
• Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273:14363–7.
   PubMed Web of Science ®Google Scholar
• Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165–76.
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309–19.
   PubMed Web of Science ®Google Scholar
• Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260–8.
   PubMed Web of Science ®Google Scholar
• Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibi-tory factor/osteoprotegerin. Biochem Biophys Res Commun 1998;247:610–5.
   PubMed Web of Science ®Google Scholar
• Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (FtANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Ftheumatology (Oxford) 2001; 40:623–30.
   PubMed Web of Science ®Google Scholar
• Abu-Amer Y, Erdmann J, Alexopoulou L, Kollias G, Ross FP, Teitelbaum SL. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 2000;275: 27307–10.
   Google Scholar
• Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y. Tumor necrosis factor-alpha (TNF) stimulates FtANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 2001;276: 563–8.
   Google Scholar
• Lubberts E, Joosten LA, Chabaud M, van Den BL, Oppers B, 61. Coenen-De Roo CJ, et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000;105: 1697–710.
   Google Scholar
• Kong YY, Feige U, Sarosi I, BoIon B, Tafuri A, Morony S, et al. 62. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, et al. TRANCE/FtANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-99. Tanaka S, Nakamura K, Oda H. The osteodast: a potential thera-peutic target of bone and joint destruction in rheumatoid arthritis. Mod Ftheumatol 2001;11: 177–83.
   Google Scholar